ClinicalTrials.gg
CompletedNCT01063062Updated Aug 21, 2017Results posted

A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)

A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 9 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-21.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
107
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
50th of 110
107 · median 97
Started
2010
with 13 others
Phase 3
65 of 110
none open now
Registered
30th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 50th largest by enrollment, is one of 14 that started in 2010, is one of 65 in phase 3, and was the 30th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This single-arm, open-label, multicenter study evaluated the safety and tolerability and the efficacy in reducing disease activity of tocilizumab [RoActemra/Actemra] as monotherapy or in combination with methotrexate in patients with active moderate to severe rheumatoid arthritis (RA). Patients were eligible to participate in this study if they are currently experiencing an inadequate response to a stable dose of a non-biologic disease-modifying antirheumatic drug (DMARD). Patients received 8 mg/kg tocilizumab [RoActemra/Actemra] as an intravenous infusion every 4 weeks for a total of 6 infusions. The anticipated time on study treatment was 24 weeks. The target sample size was 50-200 patients.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients ≥ 18 years of age
  • Moderate to severe rheumatoid arthritis (RA) for at least 6 months (defined as a Disease Activity Score (DAS28) > 3.2 at screening)
  • Patients with active RA after more than 12 weeks of treatment with DMARDs
  • Patients with inadequate response to a stable dose of non-biologic DMARD

Exclusion criteria

Exclusion Criteria:

  • disease other than RA. Patients with interstitial pulmonary fibrosis and able to tolerate methotrexate (MTX) and patients with Sjögren's Syndrome and RA are permitted
  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following enrollment
  • Prior history of or current inflammatory joint disease other than RA
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    tocilizumab

    Participants received an 8 mg/kg tocilizumab intravenous (IV) infusion once every 4 weeks for 24 weeks (6 infusions). Participants taking concomitant methotrexate (MTX) at Baseline remained on a stable dose as per standard of care at the Investigator's discretion.

    Drug: tocilizumab [RoActemra/Actemra] · Drug: Methotrexate

Interventions

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8 mg/kg intravenous infusion every 4 weeks.

  • methotrexate as per standard of care in clinical practice.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Low Disease Activity

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.

    Time frame: Baseline to Week 24 (Weeks 4, 8, 12, 16, 20, 24)

  2. Time to DAS28 Low Disease Activity

    Time to DAS28 Low Disease Activity was defined as the time in days from the first infusion of study drug to the achievement of a DAS28 Score \<3.2 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.

    Time frame: 24 Weeks

Secondary outcomes

  1. Percentage of Participants Achieving DAS28 Clinically Significant Improvement

    DAS28 Clinically Significant Improvement was defined as a DAS28 score reduction of at least 1.2 units from Baseline. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24

  2. Time to DAS28 Clinically Significant Improvement

    Time to DAS28 Clinically Significant Improvement was the Time in days from the first infusion of study drug to the achievement of a DAS28 score reduction of at least 1.2 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.

    Time frame: 24 Weeks

  3. Percentage of Participants Achieving DAS28 Remission

    DAS28 Remission was defined as a DAS28 score \< 2.6 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.

    Time frame: Weeks 4, 8, 12, 16, 20, 24

  4. Time to DAS28 Remission

    Time to DAS28 Remission was the Time in days from the first infusion of study drug to the achievement of a DAS28 score \< 2.6 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.

    Time frame: 24 Weeks

  5. Disease Activity Score 28 (DAS28)

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.

    Time frame: Weeks 4, 8, 12, 16, 20, 24

  6. C-Reactive Protein (CRP)

    Blood was collected for C-Reactive Protein (CRP), a test for inflammation, at Weeks 4, 8, 12, 16, 20 and 24 and was analyzed at a central laboratory. The serum concentration of CRP was measured in milligrams/deciliter (mg/dL).

    Time frame: Weeks 4, 8, 12, 16, 20, 24

  7. Erythrocyte Sedimentation Rate (ESR)

    Blood was collected for Erythrocyte Sedimentation Rate (ESR), a test to assess inflammation, at Weeks 4, 8, 12, 16, 20, 24 and was analyzed at a central laboratory. ESR was measured in millimeters/hour (mm/hr).

    Time frame: Weeks 4, 8, 12, 16, 20, 24

  8. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: 24 Weeks

  9. Number of Participants With AE and SAE Related Discontinuation

    The number of participants who stopped using the study drug because of an AE or a SAE. An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: 24 Weeks

  10. Number of Participants With Serious Infections

    A serious infection was an infection that qualified as a Serious Adverse Event (SAE). A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: 24 Weeks

  11. Number of Participants With Elevated AST (SGOT) and ALT (SGPT)

    Blood was collected for aspartate aminotransferase (serum glutamic oxaloacetic transaminase) \[AST/SGOT\] and alanine aminotransferase (serum glutamic pyruvic transaminase) \[ALT/SGPT\], liver function tests, and were analyzed at a central laboratory. The number of participants with High AST (SGOT) or ALT (SGPT) levels at Week 24 is reported.

    Time frame: Week 24

  12. Number of Participants With Elevated Total Cholesterol According to ATPIII Guidelines

    Blood samples were collected for Total Cholesterol and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the Total Cholesterol level in milligram/deciliter (mg/dL) was categorized as: Desirable ( \< 200), Borderline High (200- 239) or High (≥ 240). The number of participants categorized Borderline High or High at each time-point is reported.

    Time frame: Weeks 0 (Baseline), 4, 8, 12, 16, 20, 24

  13. Number of Participants With Elevated HDL Cholesterol According to ATPIII Guidelines

    Blood samples were collected for High Density Lipoprotein (HDL) Cholesterol and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the HDL Total Cholesterol level in milligram/deciliter (mg/dL) was categorized as: Low (\< 40) or High (≥ 60). The number of participants with category High at each time-point is reported.

    Time frame: Weeks 0 (Baseline), 4, 8, 12, 16, 20, 24

  14. Number of Participants With Elevated LDL Cholesterol According to ATPIII Guidelines

    Blood samples were collected for Low Density Lipoprotein (LDL) Cholesterol and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the LDL Cholesterol level in milligram/deciliter (mg/dL) was categorized as: Optimal (\< 100), Near Optimal/Above Optimal (100- 129), Borderline High (130- 159), High (160-189) or Very High (≥ 190). The number of participants categorized Borderline High, High or Very High at each time-point is reported.

    Time frame: Weeks 0 (Baseline), 4, 8, 12, 16, 20, 24

  15. Number of Participants With Elevated Triglyceride According to ATPIII Guidelines

    Blood samples were collected for Triglyceride and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the Triglyceride level in milligram/deciliter (mg/dL) was categorized as: Normal (\< 150), Borderline High (150- 199), High (200- 499) or Very High (≥ 500). The number of participants categorized Borderline High, High or Very High at each time-point is reported.

    Time frame: Weeks 0 (Baseline), 4, 8, 12, 16, 20, 24

07

Results

Posted Aug 4, 2014

Participant flow

107 participants were enrolled from 11 centers in Egypt, 2 centers were prematurely terminated.

Participant flow — Overall Study
MilestoneTocilizumabTocilizumab + MTX
Started3077
Received study drug2976
Completed2265
Not completed812
Withdrew: Patient withdrew consent01
Withdrew: Adverse event24
Withdrew: Protocol violation54
Withdrew: Investigator's request10
Withdrew: Lost to follow-up02
Withdrew: Miscellaneous reason01

Outcome measures

PrimaryPercentage of Participants Achieving Disease Activity Score 28 (DAS28) Low Disease Activity

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.

Time frame:
Baseline to Week 24 (Weeks 4, 8, 12, 16, 20, 24)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Low Disease Activity
percentage of participantsTocilizumabTocilizumab + MTX
Week 427.5918.42
Week 834.4840.79
Week 1234.4838.16
Week 1644.8347.37
Week 2062.0757.89
Week 2458.6259.21
PrimaryTime to DAS28 Low Disease Activity

Time to DAS28 Low Disease Activity was defined as the time in days from the first infusion of study drug to the achievement of a DAS28 Score \<3.2 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.

Time frame:
24 Weeks
Reported as:
Mean · days
Time to DAS28 Low Disease Activity
daysTocilizumabTocilizumab + MTX
Time to DAS28 Low Disease Activity107.2 (84.57 to 129.78)100.2 (87.49 to 112.93)
SecondaryPercentage of Participants Achieving DAS28 Clinically Significant Improvement

DAS28 Clinically Significant Improvement was defined as a DAS28 score reduction of at least 1.2 units from Baseline. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving DAS28 Clinically Significant Improvement
percentage of participantsTocilizumab MonotherapyTocilizumab + MTX
Week 462.0773.68
Week 875.8686.84
Week 1275.8690.79
Week 1679.3192.11
Week 2082.7690.79
Week 2486.2096.10
SecondaryTime to DAS28 Clinically Significant Improvement

Time to DAS28 Clinically Significant Improvement was the Time in days from the first infusion of study drug to the achievement of a DAS28 score reduction of at least 1.2 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.

Time frame:
24 Weeks
Reported as:
Mean · days
Time to DAS28 Clinically Significant Improvement
daysTocilizumab MonotherapyTocilizumab + MTX
Time to DAS28 Clinically Significant Improvement59.9 (40.20 to 79.53)41.6 (34.51 to 48.76)
SecondaryPercentage of Participants Achieving DAS28 Remission

DAS28 Remission was defined as a DAS28 score \< 2.6 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.

Time frame:
Weeks 4, 8, 12, 16, 20, 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving DAS28 Remission
percentage of participantsTocilizumab MonotherapyTocilizumab + MTX
Week 417.249.21
Week 831.0323.68
Week 1231.0327.63
Week 1634.4834.21
Week 2041.3840.79
Week 2448.2840.79
SecondaryTime to DAS28 Remission

Time to DAS28 Remission was the Time in days from the first infusion of study drug to the achievement of a DAS28 score \< 2.6 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.

Time frame:
24 Weeks
Reported as:
Mean · days
Time to DAS28 Remission
daysTocilizumabTocilizumab + MTX
Time to DAS28 Remission115.9 (94.24 to 137.49)120.5 (108.38 to 132.57)
SecondaryDisease Activity Score 28 (DAS28)

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.

Time frame:
Weeks 4, 8, 12, 16, 20, 24
Reported as:
Mean · score on a scale
Disease Activity Score 28 (DAS28)
score on a scaleTocilizumabTocilizumab + MTX
Week 4 (n=24,75)4.17 ± 1.454.48 ± 1.47
Week 83.72 ± 1.713.68 ± 1.60
Week 123.37 ± 1.623.54 ± 1.45
Week 163.25 ± 1.543.21 ± 1.43
Week 202.86 ± 1.503.11 ± 1.44
Week 242.51 ± 1.503.06 ± 1.51
SecondaryC-Reactive Protein (CRP)

Blood was collected for C-Reactive Protein (CRP), a test for inflammation, at Weeks 4, 8, 12, 16, 20 and 24 and was analyzed at a central laboratory. The serum concentration of CRP was measured in milligrams/deciliter (mg/dL).

Time frame:
Weeks 4, 8, 12, 16, 20, 24
Reported as:
Mean · mg/L
C-Reactive Protein (CRP)
mg/LTocilizumabTocilizumab + MTX
Week 413.04 ± 24.9012.28 ± 28.37
Week 8 (n=25,74)14.74 ± 35.746.24 ± 13.39
Week 129.35 ± 17.296.89 ± 15.84
Week 164.38 ± 9.983.87 ± 11.01
Week 207.92 ± 15.074.20 ± 12.11
Week 246.99 ± 13.643.82 ± 13.39
SecondaryErythrocyte Sedimentation Rate (ESR)

Blood was collected for Erythrocyte Sedimentation Rate (ESR), a test to assess inflammation, at Weeks 4, 8, 12, 16, 20, 24 and was analyzed at a central laboratory. ESR was measured in millimeters/hour (mm/hr).

Time frame:
Weeks 4, 8, 12, 16, 20, 24
Reported as:
Mean · mm/hr
Erythrocyte Sedimentation Rate (ESR)
mm/hrTocilizumab MonotherapyTocilizumab + MTX
Week 4 (n=24,27)21.08 ± 22.2720.37 ± 25.66
Week 817.18 ± 21.5413.79 ± 18.52
Week 1214.12 ± 15.1016.41 ± 22.25
Week 1615.80 ± 23.6513.88 ± 18.02
Week 2016.32 ± 25.4414.28 ± 20.42
Week 2416.32 ± 22.4316.40 ± 22.26
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
24 Weeks
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsTocilizumab MonotherapyTocilizumab + MTX
AEs2976
SAEs512
SecondaryNumber of Participants With AE and SAE Related Discontinuation

The number of participants who stopped using the study drug because of an AE or a SAE. An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
24 Weeks
Reported as:
Number · participants
Number of Participants With AE and SAE Related Discontinuation
participantsTocilizumab MonotherapyTocilizumab + MTX
Discontinuation due to AE87
Discontinuation due to SAE56
SecondaryNumber of Participants With Serious Infections

A serious infection was an infection that qualified as a Serious Adverse Event (SAE). A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
24 Weeks
Reported as:
Number · participants
Number of Participants With Serious Infections
participantsTocilizumab MonotherapyTocilizumab + MTX
Number of Participants With Serious Infections11
SecondaryNumber of Participants With Elevated AST (SGOT) and ALT (SGPT)

Blood was collected for aspartate aminotransferase (serum glutamic oxaloacetic transaminase) \[AST/SGOT\] and alanine aminotransferase (serum glutamic pyruvic transaminase) \[ALT/SGPT\], liver function tests, and were analyzed at a central laboratory. The number of participants with High AST (SGOT) or ALT (SGPT) levels at Week 24 is reported.

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With Elevated AST (SGOT) and ALT (SGPT)
participantsTocilizumab MonotherapyTocilizumab + MTX
ALT (SGPT)36
AST (SGOT)38
SecondaryNumber of Participants With Elevated Total Cholesterol According to ATPIII Guidelines

Blood samples were collected for Total Cholesterol and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the Total Cholesterol level in milligram/deciliter (mg/dL) was categorized as: Desirable ( \< 200), Borderline High (200- 239) or High (≥ 240). The number of participants categorized Borderline High or High at each time-point is reported.

Time frame:
Weeks 0 (Baseline), 4, 8, 12, 16, 20, 24
Reported as:
Number · participants
Number of Participants With Elevated Total Cholesterol According to ATPIII Guidelines
participantsTocilizumab MonotherapyTocilizumab + MTX
Week 01025
Week 41641
Week 81034
Week 12930
Week 161036
Week 20735
Week 24930
SecondaryNumber of Participants With Elevated HDL Cholesterol According to ATPIII Guidelines

Blood samples were collected for High Density Lipoprotein (HDL) Cholesterol and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the HDL Total Cholesterol level in milligram/deciliter (mg/dL) was categorized as: Low (\< 40) or High (≥ 60). The number of participants with category High at each time-point is reported.

Time frame:
Weeks 0 (Baseline), 4, 8, 12, 16, 20, 24
Reported as:
Number · participants
Number of Participants With Elevated HDL Cholesterol According to ATPIII Guidelines
participantsTocilizumab MonotherapyTocilizumab + MTX
Week 0420
Week 41034
Week 8226
Week 12622
Week 16519
Week 20220
Week 24520
SecondaryNumber of Participants With Elevated LDL Cholesterol According to ATPIII Guidelines

Blood samples were collected for Low Density Lipoprotein (LDL) Cholesterol and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the LDL Cholesterol level in milligram/deciliter (mg/dL) was categorized as: Optimal (\< 100), Near Optimal/Above Optimal (100- 129), Borderline High (130- 159), High (160-189) or Very High (≥ 190). The number of participants categorized Borderline High, High or Very High at each time-point is reported.

Time frame:
Weeks 0 (Baseline), 4, 8, 12, 16, 20, 24
Reported as:
Number · participants
Number of Participants With Elevated LDL Cholesterol According to ATPIII Guidelines
participantsTocilizumab MonotherapyTocilizumab + MTX
Week 0924
Week 41135
Week 8721
Week 12827
Week 16931
Week 20733
Week 24829
SecondaryNumber of Participants With Elevated Triglyceride According to ATPIII Guidelines

Blood samples were collected for Triglyceride and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the Triglyceride level in milligram/deciliter (mg/dL) was categorized as: Normal (\< 150), Borderline High (150- 199), High (200- 499) or Very High (≥ 500). The number of participants categorized Borderline High, High or Very High at each time-point is reported.

Time frame:
Weeks 0 (Baseline), 4, 8, 12, 16, 20, 24
Reported as:
Number · participants
Number of Participants With Elevated Triglyceride According to ATPIII Guidelines
participantsTocilizumab MonotherapyTocilizumab + MTX
Week 047
Week 4615
Week 8412
Week 12515
Week 16615
Week 20816
Week 24616

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab Monotherapy—5/29 (17.2%)29/29 (100%)
Tocilizumab + MTX—12/76 (15.8%)76/76 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventTocilizumab MonotherapyTocilizumab + MTX
Alanine aminotransferase increasedInvestigations1/291/76
GangreneInfections and infestations1/290/76
Pilonidal cystInfections and infestations1/290/76
ArthralgiaMusculoskeletal and connective tissue disorders1/291/76
Joint effusionMusculoskeletal and connective tissue disorders1/290/76
Rheumatoid arthritisMusculoskeletal and connective tissue disorders1/290/76
NeutropeniaBlood and lymphatic system disorders0/292/76
Dysfunctional uterine bleedingReproductive system and breast disorders0/291/76
ViremiaInfections and infestations0/291/76
Aspartate aminotransferase increasedInvestigations0/291/76
Most frequent other events
Showing 10 of 83
Most frequent other events
EventTocilizumab MonotherapyTocilizumab + MTX
Low density lipoprotein increasedInvestigations18/2959/76
Blood chloride increasedInvestigations16/2955/76
ArthralgiaMusculoskeletal and connective tissue disorders17/2921/76
Blood cholesterol increasedInvestigations12/2942/76
Blood calcium decreasedInvestigations12/2929/76
Blood sodium increasedInvestigations11/2928/76
Blood triglycerides increasedInvestigations9/2928/76
AnaemiaBlood and lymphatic system disorders10/2924/76
Haematocrit decreasedInvestigations7/2923/76
Haemoglobin decreasedInvestigations8/2915/76

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tocilizumab MonotherapyTocilizumab + MTXTotal
Mean37.78 ± 12.4741.76 ± 11.8440.64 ± 12.10
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab MonotherapyTocilizumab + MTXTotal
Female236992
Male7815
08

Study locations

9 sites
  • Alexandria University Hospital; Rheumatology
    Alexandria, Egypt
  • Alexandria University
    Alexandria, Egypt
  • Banha Educational Hospital; Rheumatology
    Banha, Egypt
  • Kasr El Ainy Hospital; Rheumatology
    Cairo, 11562, Egypt
  • Ain Shams University Hospital; Rheumatology
    Cairo, Egypt
  • Bab El Sheereya Hospital; Rheumatology
    Cairo, Egypt
  • El Hussein University Hospital; Rheumatology
    Cairo, Egypt
  • Kasr El Ainy Hospital
    Cairo, Egypt
  • Manial Specialized Hospital; Rheumatology
    Cairo, Egypt
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in Jan 2011, 10 months.

Results were first posted in Aug 2014, 3 years 6 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 10 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2010
First posted
Feb 5, 2010
StartActual
Feb 28, 2010
Primary completionActual
Jan 17, 2011
CompletionActual
Jan 17, 2011
Results first posted
Aug 4, 2014
Last update
Aug 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01063062
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 5, 2010
Start date
Feb 28, 2010
Primary completion
Jan 17, 2011
Completion
Jan 17, 2011
Results posted
Aug 4, 2014
Last update
Aug 21, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tocilizumab · Methotrexate

Start the discussion